DOP2011000032A - Composicion farmaceutica solida - Google Patents

Composicion farmaceutica solida

Info

Publication number
DOP2011000032A
DOP2011000032A DO2011000032A DO2011000032A DOP2011000032A DO P2011000032 A DOP2011000032 A DO P2011000032A DO 2011000032 A DO2011000032 A DO 2011000032A DO 2011000032 A DO2011000032 A DO 2011000032A DO P2011000032 A DOP2011000032 A DO P2011000032A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical composition
solid pharmaceutical
diuretic
formula
compound represented
Prior art date
Application number
DO2011000032A
Other languages
English (en)
Inventor
Junya Nomura
Yutaka Tanque
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2011000032A publication Critical patent/DOP2011000032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a una preparación sólida que contiene un compuesto representado por la formula (I) Donde cada sinbo1o es como se define en la memoria descriptiva, o una sal del mismo, un agente de control. Del pH y un diurético, el cual es superior en la. Propiedad de estabilidad y disolución del compuesto representado por la formula (I) y el diurético.
DO2011000032A 2008-07-31 2011-01-28 Composicion farmaceutica solida DOP2011000032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8520108P 2008-07-31 2008-07-31
US8562708P 2008-08-01 2008-08-01

Publications (1)

Publication Number Publication Date
DOP2011000032A true DOP2011000032A (es) 2011-02-28

Family

ID=41610805

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000032A DOP2011000032A (es) 2008-07-31 2011-01-28 Composicion farmaceutica solida

Country Status (26)

Country Link
US (1) US9169238B2 (es)
EP (1) EP2310385B1 (es)
JP (1) JP5635491B2 (es)
KR (1) KR20110038145A (es)
CN (1) CN102164918B (es)
AR (1) AR072883A1 (es)
AU (1) AU2009277455A1 (es)
BR (1) BRPI0916847A2 (es)
CA (1) CA2732018C (es)
CL (1) CL2011000187A1 (es)
CO (1) CO6341633A2 (es)
CR (1) CR20110111A (es)
DO (1) DOP2011000032A (es)
EA (1) EA201170273A1 (es)
EC (1) ECSP11010856A (es)
GE (1) GEP20146062B (es)
IL (1) IL210819A0 (es)
MA (1) MA32553B1 (es)
MX (1) MX2011001150A (es)
NZ (1) NZ590948A (es)
PE (1) PE20110551A1 (es)
PT (1) PT2310385T (es)
TW (1) TW201008915A (es)
UY (1) UY32017A (es)
WO (1) WO2010013835A2 (es)
ZA (1) ZA201100871B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
CA2882730C (en) * 2012-08-22 2019-12-31 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP6935301B2 (ja) * 2016-11-18 2021-09-15 花王株式会社 モノハロゲノアミン製造用被覆粒子群
IN202021028444A (es) * 2020-07-03 2022-01-28

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) * 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
EP1258254A4 (en) 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
JP2001294524A (ja) 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd アセトアミノフェン配合内服固形製剤
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
JP4365106B2 (ja) * 2001-05-25 2009-11-18 エスエス製薬株式会社 医薬配合剤
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
WO2005014043A1 (en) 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7625940B2 (en) * 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
US20080004320A1 (en) * 2004-09-06 2008-01-03 Kowa Co., Ltd. Remedy for Glomerular Disease
US20070049636A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
KR20070097511A (ko) * 2004-12-17 2007-10-04 베링거 인겔하임 인터내셔날 게엠베하 텔미사르탄 및 하이드로클로로티아지드를 포함하는 배합치료
KR20070116648A (ko) * 2005-03-30 2007-12-10 다케다 야쿠힌 고교 가부시키가이샤 벤즈이미다졸 유도체 및 안지오텐신 ⅱ 길항제로서의 용도
EP1885694A2 (en) 2005-05-13 2008-02-13 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
GEP20125420B (en) * 2006-08-10 2012-03-26 Takeda Pharmaceutical Solid pharmaceutical composition comprising benzimidazole compound
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
PE20130210A1 (es) 2007-03-28 2013-03-11 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
KR20100046216A (ko) 2007-08-01 2010-05-06 테바 파마슈티컬 인더스트리즈 리미티드 칸데사르탄의 약학 조성물
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
ZA201100871B (en) 2012-05-30
GEP20146062B (en) 2014-03-25
JP5635491B2 (ja) 2014-12-03
WO2010013835A2 (en) 2010-02-04
JP2011529444A (ja) 2011-12-08
CN102164918A (zh) 2011-08-24
WO2010013835A3 (en) 2010-06-10
CN102164918B (zh) 2014-05-07
CL2011000187A1 (es) 2011-06-24
EP2310385B1 (en) 2017-06-07
CO6341633A2 (es) 2011-11-21
TW201008915A (en) 2010-03-01
ECSP11010856A (es) 2011-03-31
NZ590948A (en) 2012-06-29
CA2732018C (en) 2017-07-04
EA201170273A1 (ru) 2011-08-30
IL210819A0 (en) 2011-04-28
KR20110038145A (ko) 2011-04-13
US20110123615A1 (en) 2011-05-26
UY32017A (es) 2010-02-26
US9169238B2 (en) 2015-10-27
MX2011001150A (es) 2011-03-29
AU2009277455A1 (en) 2010-02-04
MA32553B1 (fr) 2011-08-01
EP2310385A2 (en) 2011-04-20
BRPI0916847A2 (pt) 2016-02-10
AR072883A1 (es) 2010-09-29
PE20110551A1 (es) 2011-09-02
CR20110111A (es) 2011-04-28
CA2732018A1 (en) 2010-02-04
PT2310385T (pt) 2017-09-11

Similar Documents

Publication Publication Date Title
CR20110209A (es) Composición farmacéutica sólida
CL2017002792A1 (es) Derivados de ciclohexano sustituido con amido
DOP2011000032A (es) Composicion farmaceutica solida
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
SV2011003855A (es) Heteroarilos sustituidos
CR20110059A (es) Compuestos organicos
EA201001639A1 (ru) Композиции и способы их получения и применения
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY28756A1 (es) Compuestos
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
EA201270216A1 (ru) Фармацевтический состав
BR112012012903A2 (pt) compostos de espiropiperidina
DOP2011000329A (es) Preparacion de solido
TW201144306A (en) Bicyclic heteroaryl analogues as GPR119 modulators
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
PE20151155A1 (es) Derivados de carbamato/urea
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
GT200700057A (es) Nuevos derivados de piridazina
BR112016011778A2 (pt) Pirazol fluorofenila, seus usos, e composição farmacêutica
CO2019004547A2 (es) Derivado de urea